To assess whether a new treatment strategy by combining currently available approved hepatitis B medications (Telbivudine and Tenofovir) is safe and effective in reducing the level of quantitative surface antigen of hepatitis B virus (qHBsAg).


Eligibility Criteria:

Age 21 – 70 years old.

Hepatitis B carrier ≥ 6 months.

On any NA treatment (Lamivudine, Adefovir, Entecavir or Tenofovir) for ≥ 1 year.

No history of depression or psychiatric disease, autoimmune disease & cancer.




All study-related procedures, laboratory tests, consultation, ARFI scan and oral medications will be covered under the study.